BiomX (NYSEMKT:PHGE) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of BiomX (NYSEMKT:PHGE) in a research report released on Friday morning, Benzinga reports. The brokerage currently has a $2.00 price objective on the stock.

Separately, Laidlaw assumed coverage on shares of BiomX in a research note on Tuesday, May 28th. They set a buy rating and a $2.50 price target on the stock.

BiomX Stock Performance

Shares of PHGE opened at $0.16 on Friday. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $10.89 million, a P/E ratio of -0.26 and a beta of 1.32. The firm’s 50-day moving average price is $0.28 and its 200 day moving average price is $0.31.

BiomX shares are scheduled to reverse split before the market opens on Monday, August 26th. The 1-10 reverse split was announced on Thursday, August 15th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, August 23rd.

Hedge Funds Weigh In On BiomX

An institutional investor recently bought a new position in BiomX stock. Ikarian Capital LLC bought a new stake in BiomX Inc. (NYSEMKT:PHGE) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 10,817,327 shares of the company’s stock, valued at approximately $4,868,000. Ikarian Capital LLC owned 19.59% of BiomX at the end of the most recent quarter. 40.57% of the stock is owned by institutional investors.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.